Bausch Health Companies Inc. (NYSE:BHC) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC raised its stake in Bausch Health Companies Inc. (NYSE:BHC) by 62.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,301,981 shares of the company’s stock after purchasing an additional 1,263,706 shares during the period. SG Americas Securities LLC owned about 0.91% of Bausch Health Companies worth $26,614,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Goldentree Asset Management LP raised its position in Bausch Health Companies by 31.0% in the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company’s stock valued at $239,552,000 after purchasing an additional 6,958,717 shares in the last quarter. Bank of Montreal Can raised its position in Bausch Health Companies by 234.0% in the 3rd quarter. Bank of Montreal Can now owns 3,833,179 shares of the company’s stock valued at $31,598,000 after purchasing an additional 2,685,675 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Bausch Health Companies by 12.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 3,165,512 shares of the company’s stock worth $22,063,000 after acquiring an additional 341,936 shares in the last quarter. Mackenzie Financial Corp raised its position in shares of Bausch Health Companies by 111.0% during the 2nd quarter. Mackenzie Financial Corp now owns 2,381,888 shares of the company’s stock worth $16,612,000 after acquiring an additional 1,252,834 shares in the last quarter. Finally, Maple Rock Capital Partners Inc. acquired a new stake in shares of Bausch Health Companies during the 3rd quarter worth about $16,850,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Evercore ISI raised Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. Royal Bank of Canada raised their target price on Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research report on Friday, November 1st. Finally, StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research report on Friday, October 25th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, Bausch Health Companies currently has a consensus rating of “Hold” and a consensus price target of $7.75.

Bausch Health Companies Stock Up 3.4 %

NYSE:BHC opened at $7.73 on Thursday. The stock’s 50 day moving average price is $7.86 and its 200 day moving average price is $7.45. The company has a market capitalization of $2.79 billion, a PE ratio of -16.09 and a beta of 0.69. Bausch Health Companies Inc. has a 52-week low of $3.96 and a 52-week high of $11.46.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.10. The firm had revenue of $2.51 billion for the quarter, compared to the consensus estimate of $2.42 billion. Bausch Health Companies had a negative return on equity of 755.86% and a negative net margin of 1.88%. The firm’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.03 EPS. As a group, sell-side analysts anticipate that Bausch Health Companies Inc. will post 3.73 EPS for the current fiscal year.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.